Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children

Authors: Weibel, L.; Sampaio, M.C.1; Visentin, M.T.2; Howell, K.J.3; Woo, P.4; Harper, J.I.

Source: British Journal of Dermatology, Volume 155, Number 5, November 2006 , pp. 1013-1020(8)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Summary Background 

Localized scleroderma (LS) or morphoea is often considered to be a benign self-limiting condition confined to the skin and subcutaneous tissue. However, the course of the disease is unpredictable and severe functional and cosmetic disability may result. Drug treatment with systemic corticosteroids in combination with methotrexate has been reported to be beneficial in LS, but data in children is limited. Objectives 

To evaluate the efficacy and tolerability of systemic corticosteroids in combination with methotrexate in children with LS. Methods 

Treatment and outcome of 34 patients with LS were retrospectively analysed. Pulsed intravenous methylprednisolone was given, followed by oral prednisolone on a reducing regimen and maintenance treatment with methotrexate. We assessed treatment outcome clinically and by thermography and monitored adverse events. Results 

From the onset of treatment, the disease stopped progressing in 94% of the patients. All patients demonstrated significant clinical improvement within a mean time of 5·7 ± 3·9 months. Mean duration of follow-up over the treatment period and beyond was 2·9 ± 2·0 years. In 16 (47%) patients therapy was discontinued when the disease was considered to be inactive clinically; however, seven (44%) of the 16 developed a relapse, necessitating repeat treatment. At last follow-up (range 0·2-7·0 years), 24 (71%) of the 34 patients had completely inactive disease. Observed adverse events were moderate and transient and no patient had to stop therapy. Conclusions 

These data suggest that systemic corticosteroids and methotrexate in combination are beneficial and well tolerated in the treatment of children with LS. Because of the risk of relapse after discontinuing therapy, long-term monitoring is mandatory.

Keywords: localized scleroderma; methotrexate; methylprednisolone; outcome; prednisolone; treatment

Document Type: Research article

DOI: 10.1111/j.1365-2133.2006.07497.x

Affiliations: 1: Serviço de Dermatologia, Hospital Celso Pierro, JD Ipaussurama, S/N-Campinas-SP, Brazil 2: Department of Paediatric Rheumatology, University of Padova, Padova, Italy 3: Department of Rheumatology, Royal Free Hospital, London, U.K. 4: Paediatric Rheumatology, Great Ormond Street Hospital for Children, London WC1N 3JH, U.K.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$43.08 plus tax

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A